Grifols GRFS shares are trading higher on Thursday. The company announced it's working with the U.S. biomedical advanced research development authority and the FDA to collect plasma from COVID-19 patients.
The plan is to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
Grifols is a Spanish multinational pharmaceutical and chemical manufacturer headquartered in Barcelona. The company is a producer of blood plasma-based products and supplies devices, instruments, and reagents for clinical testing laboratories.
Grifols ADR class B shares were trading up 9.34% at $19.43 on Thursday. The stock has a 52-week range between $25.73 and $13.40.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
